Literature DB >> 29501742

FTO is involved in Alzheimer's disease by targeting TSC1-mTOR-Tau signaling.

Huajie Li1, Yi Ren2, Keshi Mao2, Fei Hua3, Yilin Yang4, Ning Wei2, Chunxian Yue2, Dawen Li2, Hao Zhang2.   

Abstract

Diabetes and obesity are commonly associated with Alzheimer's disease (AD). Accumulating evidence show that insulin signaling defects are protentional upstream driver of AD. However, the mechanism by which diabetes and insulin signaling defects contribute to AD remains unknown. Here we show that Fat mass and obesity-associated protein (FTO) is involved the insulin defects-associated AD. Defective insulin signaling in diabetes and obesity in human and mice activated Fto in the brain tissues. Lentivirus-mediated knockdown of Fto reduced the phosphorylation of Tau protein whereas overexpression of FTO promoted the level of phosphorylated Tau in neurons. Mechanism study demonstrated that FTO activated the phosphorylation of Tau in a mTOR-dependent manner because FTO activated mTOR and its downstream signaling and rapamycin blocked FTO-mediated phosphorylation of Tau. FTO promoted the activation of mTOR by increasing the mRNA level of TSC1 but not TSC2, the upstream inhibitor of mTOR. Finally, we found that conditional knockout of Fto in the neurons reduced the cognitive deficits in 3xTg AD mice. Collectively, our evidence demonstrated that FTO is critically involved in insulin defects-related AD.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AD; Diabetes; FTO; Insulin resistance; TSC1; Tau; mTOR

Mesh:

Substances:

Year:  2018        PMID: 29501742     DOI: 10.1016/j.bbrc.2018.02.201

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

1.  In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons.

Authors:  Ramsey Najm; Kelly A Zalocusky; Misha Zilberter; Seo Yeon Yoon; Yanxia Hao; Nicole Koutsodendris; Maxine Nelson; Antara Rao; Alice Taubes; Emily A Jones; Yadong Huang
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

Review 2.  N6-methyladenosine as a Novel Regulator of Brain Physiology and Diseases.

Authors:  Bing Han; Hong-Hong Yao
Journal:  Curr Med Sci       Date:  2020-07-17

Review 3.  Epitranscriptomic regulation by m6A RNA methylation in brain development and diseases.

Authors:  Anil K Chokkalla; Suresh L Mehta; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-23       Impact factor: 6.200

Review 4.  Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression.

Authors:  JiaLing Chen; Bin Du
Journal:  J Cancer Res Clin Oncol       Date:  2018-11-21       Impact factor: 4.553

Review 5.  m6A RNA Methylation Controls Neural Development and Is Involved in Human Diseases.

Authors:  Kunzhao Du; Longbin Zhang; Trevor Lee; Tao Sun
Journal:  Mol Neurobiol       Date:  2018-06-16       Impact factor: 5.590

6.  Ischemia-related changes of fat-mass and obesity-associated protein expression in the gerbil hippocampus.

Authors:  Woosuk Kim; Min Soo Kang; Tae Hyeong Kim; Dae Young Yoo; Joon Ha Park; Hyo Young Jung; Moo-Ho Won; Jung Hoon Choi; In Koo Hwang
Journal:  Metab Brain Dis       Date:  2019-11-30       Impact factor: 3.584

7.  MicroRNAs Regulating Autophagy in Neurodegeneration.

Authors:  Qingxuan Lai; Nikolai Kovzel; Ruslan Konovalov; Ilya A Vinnikov
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Epitranscriptomic Modifications Modulate Normal and Pathological Functions in CNS.

Authors:  Anil K Chokkalla; Suresh L Mehta; Raghu Vemuganti
Journal:  Transl Stroke Res       Date:  2021-07-05       Impact factor: 6.829

Review 9.  Role of TSC1 in physiology and diseases.

Authors:  Karthik Mallela; Arun Kumar
Journal:  Mol Cell Biochem       Date:  2021-02-11       Impact factor: 3.396

Review 10.  Epigenetic Regulation of Neuroinflammation in Parkinson's Disease.

Authors:  Madiha Rasheed; Junhan Liang; Chaolei Wang; Yulin Deng; Zixuan Chen
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.